10-Q · May 15, 2026
Ensysce Biosciences reported revenues of $1.88 million for Q4 2026, significantly exceeding estimates by over 276%. EPS was a loss of $0.75, also beating analyst expectations. However, the company continues to incur…
Earnings analysis · 10-Q
ENSC earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
Ensysce reported Q2 2026 federal grant revenue of $1.164 million, down approximately 15.1% from $1.371 million in the prior-year period, while diluted EPS improved to $(0.20) from $(0.79). The $2.571 million net loss…
Read full summary
Ensysce reported Q2 2026 federal grant revenue of $1.164 million, down approximately 15.1% from $1.371 million in the prior-year period, while diluted EPS improved to $(0.20) from $(0.79). The $2.571 million net loss shows that substantial operating losses continue despite improved per-share results. The Cy Biopharma acquisition and $38.6 million financing support liquidity, but no numeric revenue or EPS guidance was provided and further runway depends partly on an additional financing tranche.
Reported figures
- Earnings per share
- $-0.2
- Segment
- Federal grant revenue: $1.164 million
What stood out
-
Grant revenue declined year over year
Q2 2026 federal grant revenue was $1.164 million, down from $1.371 million in the prior-year period, a decline of approximately 15.1%.
-
EPS loss narrowed materially
Diluted EPS improved to $(0.20) from $(0.79) in Q2 2025 and $(0.52) in Q1 2026.
-
Loss remained substantial
The company reported a Q2 2026 net loss of $2.571 million despite the improvement in diluted EPS.
-
Funding position strengthened
The Cy Biopharma acquisition and a financing of $38.6 million improve the company’s funding position, although the additional financing tranche is subject to completion.
-
Runway extends into 2027-2028
Management indicated cash runway into late 2027, potentially extending into 2028 if the second financing tranche of up to $38.6 million is received.
What to watch
-
Persistent operating losses
The company reported a $2.571 million net loss for Q2 2026, highlighting continued cash-burn and dependence on external financing or non-dilutive funding.
-
Financing remains important
The stated cash runway extends into late 2027, while extension into 2028 depends on receiving a second financing tranche of up to $38.6 million.
-
No new risk-factor disclosure
The 10-Q does not identify new risk-factor changes and refers investors to the risk factors in the 2025 Annual Report; clinical, regulatory and execution risks therefore remain applicable.
Management's outlook
No numeric revenue or EPS guidance was provided. Management previously indicated cash runway into late 2027; a second financing tranche of up to $38.6 million could extend runway into 2028.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.